For the millions of people with peanut allergies, oral immunotherapy offers the possibility of fewer allergic reactions and a life lived with far less anxiety. That life could be on the horizon: the US Food and Drug Administration (FDA) is expected to rule on the first peanut desensitization product, Aimmune Therapeutics’ biologic, AR101, later this year.
Abbasi J. Weighing the Risks and Rewards of Peanut Oral Immunotherapy. JAMA. Published online July 31, 2019322(7):596–598. doi:10.1001/jama.2019.9142
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: